DiscoverOncology Times - OncTimes TalkAdjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer

Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer

Update: 2025-03-03
Share

Description

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undetectable postoperative PSA did not significantly improve metastasis-free survival. First author François Rozet, MD, a senior surgeon in the Department of Urology at the Institut Mutualiste.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer

Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer